ATE450268T1 - G-csf zur behandlung von amyotropher lateralsklerose - Google Patents

G-csf zur behandlung von amyotropher lateralsklerose

Info

Publication number
ATE450268T1
ATE450268T1 AT03799727T AT03799727T ATE450268T1 AT E450268 T1 ATE450268 T1 AT E450268T1 AT 03799727 T AT03799727 T AT 03799727T AT 03799727 T AT03799727 T AT 03799727T AT E450268 T1 ATE450268 T1 AT E450268T1
Authority
AT
Austria
Prior art keywords
csf
treatment
lateral sclerosis
amyotrophic lateral
gcsf
Prior art date
Application number
AT03799727T
Other languages
English (en)
Inventor
Wolf-Ruediger Schaebitz
Armin Schneider
Carola Krueger
Clemens Sommer
Stefan Schwab
Rainer Kollmar
Martin Maurer
Daniela Weber
Nikolaus Gassler
Original Assignee
Sygnis Bioscience Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sygnis Bioscience Gmbh & Co Kg filed Critical Sygnis Bioscience Gmbh & Co Kg
Priority claimed from PCT/IB2003/006446 external-priority patent/WO2004058287A2/en
Application granted granted Critical
Publication of ATE450268T1 publication Critical patent/ATE450268T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
AT03799727T 2002-12-31 2003-12-31 G-csf zur behandlung von amyotropher lateralsklerose ATE450268T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33175502A 2002-12-31 2002-12-31
US10/659,295 US7785601B2 (en) 2002-12-31 2003-09-11 Methods of treating neurological conditions with hematopoietic growth factors
PCT/IB2003/006446 WO2004058287A2 (en) 2002-12-31 2003-12-31 Methods of treating neurological conditions with hematopoeitic growth factors

Publications (1)

Publication Number Publication Date
ATE450268T1 true ATE450268T1 (de) 2009-12-15

Family

ID=32710846

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03799727T ATE450268T1 (de) 2002-12-31 2003-12-31 G-csf zur behandlung von amyotropher lateralsklerose

Country Status (8)

Country Link
US (8) US7785601B2 (de)
EP (2) EP2311483A1 (de)
JP (2) JP4733521B2 (de)
CN (3) CN101693107A (de)
AT (1) ATE450268T1 (de)
AU (1) AU2009201467A1 (de)
DE (1) DE60330390D1 (de)
RU (1) RU2008146718A (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1019082B2 (de) * 1997-10-02 2008-06-04 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Verwendung eines kolonie-stimulierenden faktors (csf) zum verstärken des kollateralen wachstums von kollateralen arterien und / oder anderer arterien aus bestehenden arteriolären verbindungen
EP2095823A1 (de) * 2002-07-30 2009-09-02 Stem Cell Therapeutics Inc. Oligodendrozytenherstellung aus multipotenten neuralen Stammzellen
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
WO2004058287A2 (en) * 2002-12-31 2004-07-15 Axaron Bioscience Ag Methods of treating neurological conditions with hematopoeitic growth factors
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7884188B2 (en) 2003-06-02 2011-02-08 Varleigh Immuno Pharmaceuticals (Vip) Ltd Complement inhibitors
AU2005306894B2 (en) * 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
US20060257943A1 (en) * 2005-01-25 2006-11-16 Cis Biotech, Inc. Ischemic biomarkers and their use to predict adverse neurological events from surgery
US20070031373A1 (en) * 2005-08-04 2007-02-08 Carlos Lopez Reversal of Adult Onset Disorders with Granulocyte-Colony Stimulating Factors
AU2006281994B2 (en) * 2005-08-19 2011-10-06 Commonwealth Scientific And Industrial Research Organisation Arachnocampa luciferases
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
US20070196279A1 (en) * 2006-02-21 2007-08-23 Shen Che-Kun J Methods for treating progressive neurodegenerative disorders
US9770485B2 (en) * 2006-02-21 2017-09-26 Academia Sinica Methods for rescuing learning and/or memory deficits caused by alzheimer's disease by G-CSF
WO2007105305A1 (ja) * 2006-03-14 2007-09-20 Japan Tobacco Inc. 新規なβ－ガラクトシド－α２，６－シアル酸転移酵素、それをコードする遺伝子およびその製造方法
JP5153114B2 (ja) * 2006-10-12 2013-02-27 知宏 千葉 新規のアルツハイマー病検出方法
KR100812274B1 (ko) * 2006-10-30 2008-03-13 한양대학교 산학협력단 Ｇ-ｃｓｆ를 유효성분으로 하는 당뇨성 말초신경병 예방 및치료제
EP2089049A4 (de) * 2006-11-17 2011-11-16 Biogen Idec Inc Systemische verabreichung kolonienstimulierender faktoren zur behandlung von amyloid-assoziierten erkrankungen
JP2010514431A (ja) * 2006-12-29 2010-05-06 エボニック デグサ ゲーエムベーハー 生成物阻害が低減されたメチオニンシンターゼ
US7618938B2 (en) * 2007-02-07 2009-11-17 Academia Sinica Treating cerebrovascular diseases with erythropoietin and granulocyte-colony stimulating factor jointly
US7723302B2 (en) * 2007-05-01 2010-05-25 Florida Atlantic University Method of treating Parkinson's disease
JP4927774B2 (ja) * 2007-10-12 2012-05-09 サントリーホールディングス株式会社 Ｕｄｐ−グルクロン酸転移酵素およびそれをコードするポリヌクレオチド
WO2009055454A2 (en) * 2007-10-22 2009-04-30 University Of Florida Research Foundation, Inc. Xylan-utilization regulon for efficient bioprocessing of hemicellulose and uses thereof
TW200948964A (en) * 2008-04-17 2009-12-01 Novozymes As Laccase variants
CN102215860A (zh) * 2008-08-05 2011-10-12 南佛罗里达大学 治疗认知损害的方法
US9132168B2 (en) * 2008-08-05 2015-09-15 University Of South Florida Methods of treating cognitive impairment
JP5709751B2 (ja) * 2008-09-04 2015-04-30 エイビーティー ホールディング カンパニー ニューロンの軸索退縮を予防するための幹細胞の使用
EP2362899A1 (de) 2008-10-31 2011-09-07 Katholieke Universiteit Leuven Optimierte verfahren zur differenzierung von zellen zu zellen mit hepatozyt- und hepatozytenvorläufer-phänotypen, mit den verfahren produzierte zellen und verfahren zur verwendung der zellen
AU2010216083A1 (en) * 2009-02-17 2011-08-18 Sygnis Bioscience Gmbh & Co. Kg Use of G-CSF for the extension of the therapeutic time-window of thrombolytic stroke therapy
SG10201404280XA (en) * 2009-07-21 2014-10-30 Abt Holding Co Use of stem cells to reduce leukocyte extravasation
AU2010276264B2 (en) * 2009-07-21 2013-09-19 Abt Holding Company Use of stem cells to reduce leukocyte extravasation
EP2502079B1 (de) * 2009-11-20 2015-01-28 Pharnext Neue diagnose für die charcot-marie-tooth-krankheit
US8652813B2 (en) * 2009-11-25 2014-02-18 Codexis, Inc. Recombinant Thermoascus aurantiacus β-glucosidase variants
CA2785612C (en) 2010-01-08 2019-09-10 Varleigh Immuno Pharmaceuticals (Vip) Ltd. Ev576 for use in the treatment of viral infections of the respiratory tract
WO2017120461A1 (en) 2016-01-08 2017-07-13 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US9795652B2 (en) * 2010-02-25 2017-10-24 University Of South Florida Use of endogenous antioxidant proteins in the treatment of stroke
CN102260343A (zh) 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 重组人g-csf二聚体在治疗神经损伤疾病中的用途
US9090878B2 (en) 2010-06-17 2015-07-28 Katholieke Universiteit Leuven Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells
GB201011589D0 (en) * 2010-07-09 2010-08-25 Reneuron Ltd Therapeutic cells
WO2012083128A2 (en) * 2010-12-16 2012-06-21 The Mclean Hospital Corporation Prevention and treatment of diseases characterized by mesencephalic dopaminergic neuron cell death
US9161968B2 (en) * 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
CN102212542B (zh) * 2011-04-11 2012-12-19 上海赛伦生物技术有限公司 重组马gmcsf的制备方法及相关马gmcsf核苷酸序列
DK2734634T3 (da) * 2011-07-22 2019-10-21 Univ Chicago Igf-1 til anvendelse til behandling af migræne
EP2737905B1 (de) 2011-07-25 2019-09-11 Generon (Shanghai) Corporation Ltd. Verwendung eines g-csf-dimer bei der herstellung eines medikaments zur behandlung von neurodegenerativen erkrankungen
CN103930543B (zh) * 2011-09-06 2020-11-27 诺维信公司 葡糖淀粉酶变体和编码它们的多核苷酸
US9632075B2 (en) * 2011-11-01 2017-04-25 Meselex, Inc. Prevention or attenuation of neuropathic pain by bile acids
US8889630B2 (en) 2011-12-23 2014-11-18 Carlos Lopez Method for hair regrowth using Granulocyte-Colony Stimulating Factor
WO2013149064A1 (en) * 2012-03-30 2013-10-03 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Uridine diphosphate compounds as mobilizers of hematopoietic progenitor cells
CN113559282A (zh) * 2012-07-19 2021-10-29 宾夕法尼亚州研究基金会 再生用于在神经系统中治疗疾病和损伤的功能性神经元
CN103193882B (zh) * 2013-03-29 2014-11-05 浙江大学 胚胎干细胞特异性标志物GM-CSFRα及其应用
KR102161726B1 (ko) 2013-04-12 2020-10-06 사베리오 라프란체스카 이식용 장기의 개선
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
EP3079708A4 (de) 2013-12-09 2017-08-30 The Board of Trustees of the Leland Stanford Junior University Verfahren und zusammensetzungen zur behandlung von altersassoziierten leiden
WO2015185602A1 (en) * 2014-06-04 2015-12-10 Affiris Ag Treatment and prevention of parkinson's disease (pd)
US10039808B2 (en) 2014-10-22 2018-08-07 Michael Chez Method of treating or improving neurological function in a human subject
US9925244B1 (en) 2015-02-17 2018-03-27 Michael Chez Treatment of warts in non-immunosuppressed patients
PT3307296T (pt) 2015-06-15 2022-01-07 Univ Leland Stanford Junior Timp2 para uso no tratamento de condições associadas ao envelhecimento
EP3426265B1 (de) 2016-04-28 2021-09-22 Alkahest, Inc. Plasmafraktionen als therapie von tumorwachstum und -progression
IL304946A (en) 2016-08-18 2023-10-01 Alkahest Inc Blood plasma fractions as a treatment for cognitive disorders associated with aging
EA039316B1 (ru) 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
BR112019022402A2 (pt) 2017-04-26 2020-05-19 Alkahest Inc regime de dosagem para tratamento de comprometimentos cognitivo e motor com plasma sanguíneo e produtos de plasma sanguíneo
CN108404118A (zh) * 2017-06-14 2018-08-17 张建宁 人源乳凝集素亚型蛋白的新用途
US10863912B2 (en) 2017-08-24 2020-12-15 Myneurva Holdings, Inc. System and method for analyzing electroencephalogram signals
WO2019075053A1 (en) 2017-10-11 2019-04-18 Elanco Us Inc. PORCINE G-CSF VARIANTS AND USES THEREOF
US11692029B2 (en) 2018-03-05 2023-07-04 The Schepens Eye Research Institute, Inc. Therapy for glaucoma and optic neuropathy by targeting colony stimulating factors
MX2021004755A (es) 2018-10-26 2021-06-08 Alkahest Inc Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
MX2023003655A (es) 2020-09-29 2023-06-22 Neuexcell Therapeutics Inc Vector neurod1.
CA3242855A1 (en) * 2022-02-11 2023-08-17 Partner Therapeutics, Inc. Treatments based on the granulocyte and macrophage colony stimulation factor against neurodegenerative or neurological diseases or disorders
US20240058419A1 (en) * 2022-08-22 2024-02-22 Buddhist Tzu Chi Medical Foundation Method for treating optic neuropathy

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US6004548A (en) 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
US5641663A (en) 1985-11-06 1997-06-24 Cangene Corporation Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
EP0231819B1 (de) * 1986-01-22 1992-04-01 Chugai Seiyaku Kabushiki Kaisha Pharmazeutischer Stoff für die Behandlung von myelogener Leukämie
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
US5059909A (en) 1986-09-30 1991-10-22 Colloidal Dynamics Pty. Ltd. Determination of particle size and electrical charge
NO176799C (no) 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
US5214132A (en) 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
GB2213821B (en) 1987-12-23 1992-01-02 British Bio Technology Synthetic human granulocyte colony stimulating factor gene
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5599690A (en) 1988-02-01 1997-02-04 Amgen Inc. Control of norleucine incorporation into recombinant proteins
US5021239A (en) 1988-03-21 1991-06-04 Genetics Institute, Inc. Use of M-CSF to improve lipoprotein cholesterol profiles
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
EP0344796B1 (de) 1988-06-03 1994-09-21 Chugai Seiyaku Kabushiki Kaisha Menschlicher kristallinischer Granulocyt-Koloniestimulierungsfaktor und dessen Herstellung
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5629283A (en) 1989-08-11 1997-05-13 Amrad Corporation Limited Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
EP0439952A3 (en) 1990-01-31 1992-09-09 Sgs-Thomson Microelectronics, Inc. Dual-port cache tag memory
US5492534A (en) 1990-04-02 1996-02-20 Pharmetrix Corporation Controlled release portable pump
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
JP2946231B2 (ja) 1990-05-31 1999-09-06 株式会社栗本鐵工所 超微粉分級機
JPH04198134A (ja) 1990-11-28 1992-07-17 Eisai Co Ltd 老人性痴呆症の治療・予防剤
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
JP3537151B2 (ja) 1991-12-26 2004-06-14 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
WO1994028919A1 (fr) * 1993-06-08 1994-12-22 Ajinomoto Co., Inc. Accelerateur de la proliferation des cellules hematopietiques
US6465616B1 (en) * 1994-04-08 2002-10-15 Bresagen Limited Interleukin-5 antagonist
US5585245A (en) 1994-04-22 1996-12-17 California Institute Of Technology Ubiquitin-based split protein sensor
US5474552A (en) 1994-06-27 1995-12-12 Cb-Carmel Biotechnology Ltd. Implantable drug delivery pump
DE19518505A1 (de) 1995-05-19 1996-11-21 Max Planck Gesellschaft Verfahren zur Genexpressionsanalyse
US5995860A (en) 1995-07-06 1999-11-30 Thomas Jefferson University Implantable sensor and system for measurement and control of blood constituent levels
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
CA2213906A1 (en) * 1996-09-23 1998-03-23 Dusica Maysinger Pharmaceutical composition and method for neuron rescue in ischemic stroke
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
US5895647A (en) * 1996-12-20 1999-04-20 The United States Of America As Represented By The Secretary Of The Navy Use of oral interleukin-6 as therapy for hemorrhagic shock
JP3503418B2 (ja) 1997-05-15 2004-03-08 ミノルタ株式会社 誘導加熱定着装置
US20010049381A1 (en) * 1997-06-04 2001-12-06 Gpl Nil Holdings, Inc., Pyrrolidine derivative hair growth compositions and uses
US6093167A (en) 1997-06-16 2000-07-25 Medtronic, Inc. System for pancreatic stimulation and glucose measurement
EP1019082B2 (de) 1997-10-02 2008-06-04 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Verwendung eines kolonie-stimulierenden faktors (csf) zum verstärken des kollateralen wachstums von kollateralen arterien und / oder anderer arterien aus bestehenden arteriolären verbindungen
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
EP1068356B8 (de) 1998-04-03 2007-01-03 Adnexus Therapeutics, Inc. Adressierbare protein arrays
AU752272B2 (en) 1998-05-22 2002-09-12 Smithkline Beecham Corporation G-CSF mimetics
JP2002516328A (ja) 1998-05-22 2002-06-04 スミスクライン・ビーチャム・コーポレイション Ｇ−ｃｓｆ模倣物
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
WO2000004926A2 (en) 1998-07-22 2000-02-03 Osprey Pharmaceuticals Limited Conjugates for treating inflammatory disorders and associated tissue damage
US6554798B1 (en) 1998-08-18 2003-04-29 Medtronic Minimed, Inc. External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities
US6261250B1 (en) 1998-08-20 2001-07-17 Rle Corporation Method and apparatus for enhancing cardiovascular activity and health through rhythmic limb elevation
US6610540B1 (en) 1998-11-18 2003-08-26 California Institute Of Technology Low oxygen culturing of central nervous system progenitor cells
WO2000044785A1 (en) 1999-01-29 2000-08-03 F. Hoffmann-La Roche Ag Gcsf conjugates
EP1234027A1 (de) * 1999-12-03 2002-08-28 Human Genome Sciences, Inc. Cytokinrezeptor-ähnliche polynukleotide, polypeptide und antikörper
DE10033219A1 (de) 2000-07-07 2002-01-24 Univ Heidelberg Neuroprotektive Wirkung von Granulocyten-Colony Stimmulierendem Faktor (G-CSF)
WO2002018440A1 (en) * 2000-09-01 2002-03-07 Bioacta Limited Anti-angiogenic peptides
AU9084601A (en) 2000-09-08 2002-03-22 Massachusetts Inst Technology G-csf analog compositions and methods
AU2001286221B2 (en) 2000-09-13 2006-09-28 Chugai Seiyaku Kabushiki Kaisha Remedies for ischemic diseases
WO2002037968A1 (en) * 2000-11-10 2002-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating disorders of neuronal deficiency with bone marrow-derived cells
JP3607271B2 (ja) 2001-03-12 2005-01-05 株式会社Ｇｂｓ研究所 神経損傷の治療薬
JP3763749B2 (ja) 2001-03-28 2006-04-05 独立行政法人科学技術振興機構 脊髄におけるシナプス形成ニューロンを誘導する中枢神経系前駆細胞
US20020198150A1 (en) * 2001-06-07 2002-12-26 Ayelet Chajut Methods of using colony stimulating factors in the treatment of tissue damage and ischemia
FR2834898B1 (fr) 2002-01-18 2005-06-10 Didier Pourquier Nouvelle application therapeutique du g-csf, du gm-csf et du scf
DE10211063A1 (de) 2002-03-13 2003-10-09 Axaron Bioscience Ag Neue Verfahren zur Detektion und Analyse von Protein-Interaktionen in vivo
WO2003094950A2 (en) 2002-05-10 2003-11-20 Ipf Pharmaceuticals Gmbh A method of inhibiting the emigration of cells from the intravascular compartment into tissues
EP1556033A4 (de) * 2002-05-17 2006-05-31 Celgene Corp Verfahren und zusammensetzungen mit selektiven cytokin-hemmenden arzneimitteln zur behandlung und versorgung von krebs und anderen erkrankungen
DK1505973T3 (da) * 2002-05-17 2010-05-31 Celgene Corp Kombinationer til behandling af multipelt myelom
EP2095823A1 (de) 2002-07-30 2009-09-02 Stem Cell Therapeutics Inc. Oligodendrozytenherstellung aus multipotenten neuralen Stammzellen
AU2003286611A1 (en) * 2002-10-24 2004-05-13 Sangstat Medical Corporation Cytomodulating peptides and methods for treating neurological disorders
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
JP4198134B2 (ja) 2005-04-13 2008-12-17 京セラミタ株式会社 給紙装置
EP2036571A1 (de) * 2007-09-13 2009-03-18 Sygnis Bioscience GmbH & Co. KG Verwendung von G-CSF für die Behandlung von Schlaganfall

Also Published As

Publication number Publication date
CN1756556A (zh) 2006-04-05
US8053407B2 (en) 2011-11-08
JP2010270158A (ja) 2010-12-02
JP4733521B2 (ja) 2011-07-27
EP2311483A1 (de) 2011-04-20
US7785601B2 (en) 2010-08-31
US20080181865A1 (en) 2008-07-31
JP2006512419A (ja) 2006-04-13
US20080171080A1 (en) 2008-07-17
RU2008146718A (ru) 2010-06-10
US7884069B2 (en) 2011-02-08
AU2009201467A1 (en) 2009-05-14
US20120231065A1 (en) 2012-09-13
US20080279814A1 (en) 2008-11-13
US20080175894A1 (en) 2008-07-24
US20040141946A1 (en) 2004-07-22
US20080241097A1 (en) 2008-10-02
CN101693107A (zh) 2010-04-14
US20090087481A1 (en) 2009-04-02
EP2186525A3 (de) 2011-02-09
US8071543B2 (en) 2011-12-06
EP2186525A2 (de) 2010-05-19
DE60330390D1 (de) 2010-01-14
CN101926981A (zh) 2010-12-29
CN100558397C (zh) 2009-11-11

Similar Documents

Publication Publication Date Title
DE60330390D1 (de) G-csf zur behandlung von amyotropher lateralsklerose
ATE170082T1 (de) Verfahren zur wachstumshemmung von leukämischen zellen durch her-2-protein-zeilen
DE60329756D1 (de) Mitotische kinesin-hemmer
DE60231439D1 (de) Mitotische kinesinhemmer
DE60234278D1 (de) Mitotische kinesin-hemmer
CY1108927T1 (el) Αναστολεις μιτωτικης κινεσινης
IL250826A0 (en) Methods for treating bone cancer pain by administering a growth factor antagonist
ATE264869T1 (de) Glucagonähnliche, insulinotrope komplexe, ihre zusammensetzungen und ihr herstellungsverfahren
ATE372341T1 (de) Inhibitoren von mitotischem kinesin
DE69328474D1 (de) Verwendung von substituierten Adeninderivaten zur Behandlung von MultipleSklerose
PL379983A1 (pl) Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje
DE68929566D1 (de) Verfahren zur Isolierung und Reinigung von G-CSF
DE69902154D1 (de) Eisen-dextran verbindung zur verwendung als komponente in einer therapeutischen zusammensetzung zur behandlung oder prophylaxe von eisenmangel, sowie verfahren zur herstellung der eisen-dextran verbindung und ihre anwendung zur herstellung einer parenteral anwendbaren therapeutischen zubereitung.
WO2004058287A3 (en) Methods of treating neurological conditions with hematopoeitic growth factors
WO2005065183A3 (en) Mitotic kinesin inhibitors
DE69231093D1 (de) Verwendung einer zellulären Zusammensetzung zur Behandlung von menschlichen oder tierischen Organismen
DE60034110D1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
ATE426605T1 (de) Inhibitoren von mitotischem kinesin
ATE453386T1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
ATE342372T1 (de) Verfahren zur herstellung von d-pantothensäure und/oder deren salze als zusatz zu tierfuttermitteln
ATE349544T1 (de) Verfahren zur herstellung von d-pantothensäure und/oder deren salze als zusatz zu tierfuttermitteln
DE60303296D1 (de) Verwendung von (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten
WO2004043353A3 (en) Compositions and methods for treating acute myeloid leukemia
ATE350034T1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus
ATE269090T1 (de) Tiermodell zum testen von arzneistoffen zur behandlung von leukämie oder hiv

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties